Medically reviewed on August 28, 2017.
Applies to the following strengths: 0.5 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Multiple Sclerosis
0.5 mg orally once daily
Comments: Monitor with first dose (see WARNINGS section).
Use: For the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
Mild to moderate hepatic impairment: No adjustment recommended.
Severe hepatic impairment: Closely monitor patients.
The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for fingolimod. It includes a communication plan. For additional information: www.fda.gov/REMS.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Take with or without food.
-Doses higher than 0.5 mg are associated with a greater incidence of adverse reactions without additional benefit.
Storage requirements: Store at room temperature in the original blister pack; protect from moisture.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about fingolimod
- Fingolimod Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- En Español
- 74 Reviews
- Drug class: selective immunosuppressants
Other brands: Gilenya